Impra vascular graft tracking variance request needs clarification, FDA says.
This article was originally published in The Gray Sheet
Executive Summary
IMPRA'S ALTERNATE PROCEDURES FOR TRACKING VASCULAR GRAFTS need clarification before FDA can approve them, the agency says in a recent response to an Impra petition filed in March 1994. FDA informs the company that "the agency has been unable, thus far, to determine whether it should grant the tracking variance requested in the petition, due to the need for the firm to provide and clarify certain information."
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.